Media stories about Vascular Biogenics (NASDAQ:VBLT) have trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vascular Biogenics earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.0220384759177 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Vascular Biogenics (VBLT) traded down 0.82% on Friday, hitting $6.05. The company had a trading volume of 239,669 shares. The stock’s market capitalization is $163.40 million. The firm’s 50 day moving average price is $5.96 and its 200-day moving average price is $5.26. Vascular Biogenics has a 52 week low of $3.90 and a 52 week high of $7.25.
Vascular Biogenics (NASDAQ:VBLT) last released its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.01. Analysts forecast that Vascular Biogenics will post ($0.74) earnings per share for the current fiscal year.
Several equities analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Vascular Biogenics in a research report on Tuesday, October 3rd. Zacks Investment Research raised Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th. Finally, ValuEngine upgraded Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $14.75.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/28/vascular-biogenics-vblt-earning-somewhat-positive-press-coverage-accern-reports.html.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.